Table 4.

Analysis of factors predictive of EFS and OS.

Parameter	Event-Free Survival				Overall Survival
	Univariate analysis		Multivariate analysisa		Univariate analysis		Multivariate analysis
	P value	Hazard Ratio	P value	Hazard Ratio	P value	Hazard Ratio	P value	Hazard Ratio
Age (<41 years)	0.21				0.37
No BM involvement	0.49				0.39
Immunophenotype	0.31				0.45
Stage (I, II, III, IV)	0.15				0.47
LDH > normal	0.08				0.004	2.88	0.03	2.37
> 1 extranodal site	0.46				0.76
< 3 prior regimens	0.11				0.007	2.78	0.07	2.10
Sensitive disease at BMT	0.005	2.53	0.005	2.53	0.08
KPS < 80	0.13				0.01	0.37
Rituximabb	0.35, 0.16,				0.61, 0.30,
	0.46				0.08
sAAIPI (Lc, LI, HI, H)	0.07				0.01	1.00
						0.81
						1.84
						4.38

^aMultivariate analysis excludes sAAIPI;

^bTreatment with Rituximab (pre-, post- or pre- and post-HSCT) was analyzed in 42 patients with B-cell immunophenotype;

^cL: low risk; LI: low-intermediate risk; HI: high-intermediate risk; H: high risk.